TG Therapeutics reports positive phase 1 data for BRIUMVI in myasthenia gravis

June 9, 2026 7:30 AM

TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from a phase 1 study of subcutaneous BRIUMVI in patients with myasthenia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found